Action 002773 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Chengdu Kanghong Pharmaceutical Group Co., Ltd

Actions

002773

CNE1000020C4

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 12/06/2024 		Varia. 5j. Varia. 1 janv.
22,67 CNY -1,13 % Graphique intraday de Chengdu Kanghong Pharmaceutical Group Co., Ltd +0,67 % +22,94 %
04/06 Kanghong Pharmaceutical obtient le feu vert des autorités pour son collyre au pranoprofène MT
29/04 Une unité de Kanghong Pharmaceutical reçoit le feu vert de la FDA pour tester un médicament contre la dégénérescence maculaire MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Kanghong Pharmaceutical Gets Regulatory Nod for Pranoprofen Eye Drop
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 May 2024
Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug
Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid
Kanghong Pharmaceutical's Beijing Unit Gets China's Approval for Clinical Trials for Anti-Tumor Injection
Kanghong Pharmaceutical's Unit Gets Nod to Trial Psoriasis Drug
Kanghong Pharmaceutical Gets Nod for Registration of Escitalopram Oxalate Tablets
Kanghong Pharma's Aripiprazole Oral Solution Chosen for China's Centralized Drug Procurement
Kanghong Pharma Gets FDA Nod to Trial Drug Against Fatty Liver Disease
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
Kanghong Pharmaceutical Gets US FDA's Clinical Trial Nod for Antidepressant
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Executive Changes
Kanghong Pharma Gets Nod to Trial Antidepressant
Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership)
Kanghong Pharma Gets Continued Protection for Traditional Chinese Medicine
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 002773
  4. Actualités Chengdu Kanghong Pharmaceutical Group Co., Ltd
  5. Autres langues